Clinical Progress of Aerie Pharmaceuticals’ Rhopressa and Roclatan

Tom Mitro, chief operating officer of Aerie Pharmaceuticals, brought the OIS@ASCRS community up-to-date on the clinical progress for Rhopressa and Roclatan. The company is entering launch mode for the former, with an NDA filed in February. Roclatan, meanwhile, is the subject of two ongoing Phase III trials.